Glucagon’s Redemption: Dual-Hormone Drugs Outpace GLP-1s on Triglycerides

Key Takeaway: A large-scale meta-analysis covering more than 6,600 participants reveals that a new class of dual-hormone drugs targeting both GLP-1 and glucagon receptors not only delivers significant weight loss but also lowers triglycerides far more effectively than today’s widely used GLP-1 receptor agonists alone. This finding suggests these drugs are not merely a more potent version of existing therapies but offer a qualitatively distinct metabolic profile.

Two Hormones, One Drug, and a Metabolic Conundrum

The weight-loss drug revolution of the past few years has been shaped around a single gut hormone: GLP-1. Medications like semaglutide and liraglutide have transformed our approach to obesity and type 2 diabetes, delivering double-digit percentage reductions in body weight once achievable only through surgery^[2]. But what if pairing GLP-1 with a second hormone—one that, on its own, paradoxically raises blood sugar—could unlock metabolic benefits that GLP-1 alone cannot reach?

That second hormone is glucagon. For decades, glucagon was viewed as the “villain” in diabetes management: the counter-regulatory signal that pushes blood sugar up while insulin pulls it down^[3]. The idea of intentionally activating the glucagon receptor in people with metabolic disease seemed counterintuitive, even reckless. Yet a growing body of research has shown that glucagon also potently stimulates fat burning in the liver, increases energy expenditure, and indirectly contributes to satiety through hepatic-neural signaling pathways^[4]. A new class of dual GLP-1 receptor/glucagon receptor (GLP-1R/GCGR) agonists is designed to harness both hormones at once, and a comprehensive meta-analysis now provides the clearest picture yet of what this combination achieves.

How the Study Was Conducted

Researchers pooled data from 16 randomized controlled trials involving a total of 6,611 participants. These trials evaluated dual GLP-1R/GCGR agonists, which are designed to activate both GLP-1 and glucagon receptors in a single molecule. The meta-analysis examined not only weight loss but also a broad panel of cardiometabolic markers, including waist circumference, blood lipids, and HbA1c (a measure of average blood sugar over approximately three months). Crucially, the analysis included head-to-head comparisons between the dual agonists and selective GLP-1 receptor agonists, allowing researchers to determine whether the addition of glucagon receptor activation provides benefits beyond what GLP-1 alone can deliver.

Key Findings

Compared to placebo, dual GLP-1R/GCGR agonists reduced body weight by an average of 7.44%, corresponding to approximately 7.27 kilograms (about 16 pounds)^[1]. This weight loss was accompanied by significant reductions in waist circumference, a marker closely associated with metabolically hazardous visceral fat surrounding the internal organs. HbA1c also improved significantly, confirming that glucagon receptor activation did not adversely affect blood sugar control.

The lipid findings were particularly striking. The dual agonists significantly lowered total cholesterol, LDL cholesterol (the so-called “bad” cholesterol), and triglycerides compared to placebo. But the most noteworthy result came from the direct comparison with selective GLP-1 receptor agonists: the dual agonists reduced triglycerides by an additional 0.28 mmol/L on top of the reduction provided by GLP-1 drugs on their own. In a field where small improvements in lipids translate to meaningful reductions in cardiovascular events over time^[5], this difference is substantial.

Why Glucagon Changes the Lipid Equation

To understand why adding glucagon receptor activation lowers triglycerides more effectively, one must look to the liver. The liver is the body’s central processing plant for fats. It packages fatty acids into triglyceride-rich lipoproteins—primarily very-low-density lipoprotein, or VLDL—and exports them into the bloodstream. When excess fat accumulates in the liver, as is common in obesity and type 2 diabetes, VLDL production ramps up, and circulating triglyceride levels rise^[6].

GLP-1 receptor agonists modestly lower triglycerides, largely as a secondary consequence of weight loss and improved insulin sensitivity. But glucagon acts on the liver through a fundamentally different mechanism. Activating the glucagon receptor stimulates hepatic fatty acid oxidation—in essence, it tells liver cells to burn stored fat for energy rather than repackaging it for export^[4]. This reduces the raw material available for VLDL synthesis, cutting off triglyceride production at the source. Glucagon also increases hepatic energy expenditure and may enhance bile acid signaling, further contributing to lipid clearance^[7].

The result is a two-pronged metabolic intervention. GLP-1 receptor activation suppresses appetite, slows gastric emptying, and improves insulin secretion. Glucagon receptor activation complements these effects by directly reprogramming hepatic lipid metabolism. The combination not only produces “more” weight loss but also generates a qualitatively different metabolic signature that specifically targets the atherogenic dyslipidemia (high triglycerides, increased small dense LDL particles) that drives cardiovascular risk in metabolic disease.

Limitations to Consider

No single meta-analysis rewrites clinical practice. While pooling 16 studies increases statistical power, the individual trials varied in duration, dosage, and patient populations. Most studies were relatively short-term, meaning we don’t yet know if these triglyceride benefits persist over years or translate into fewer heart attacks and strokes. The paradox of intentionally activating the glucagon receptor in people prone to high blood sugar also warrants long-term safety monitoring—although HbA1c improved in these analyses, the balance between GLP-1 and glucagon receptor activation must be carefully calibrated. Finally, many of these drugs are still in mid-to-late-stage development, and real-world effectiveness may differ from controlled trial settings.

Implications for the Future

For the millions of people living with obesity, type 2 diabetes, and the accompanying high triglycerides, this meta-analysis carries a clear message: the next generation of metabolic drugs may not only help patients lose weight but also reshape their cardiovascular risk profiles in ways current treatments cannot fully accomplish. The superior triglyceride lowering seen with dual agonists compared to GLP-1 drugs alone suggests that glucagon receptor activation fills a true therapeutic gap—especially for patients whose lipid abnormalities persist despite weight loss.

The next step for the research community is equally clear. To claim a definitive advantage, large-scale cardiovascular outcomes trials designed to track whether these lipid improvements actually prevent heart attacks, strokes, and cardiovascular death are essential. But the biological rationale is compelling, the early data are consistent, and the unmet need is vast. Glucagon, once seen as the enemy of diabetes, may be on the verge of a remarkable clinical redemption.

Scientific Sources

1. Roessler J, et al. Cardiometabolic Effects of Dual GLP-1 and Glucagon Receptor Agonists: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes care. 2026. PubMed: https://pubmed.ncbi.nlm.nih.gov/42627353/
2. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. DOI: 10.1056/NEJMoa2032183
3. Unger RH, et al. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest. 2012. DOI: 10.1172/JCI60016
4. Habegger KM, et al. The metabolic actions of glucagon revisited. Nat Rev Endocrinol. 2010. DOI: 10.1038/nrendo.2010.187
5. Nordestgaard BG, et al. Triglycerides and cardiovascular disease. Lancet. 2014. DOI: 10.1016/S0140-6736(14)61177-6
6. Fabbrini E, et al. Hepatic steatosis as a marker of metabolic dysfunction. Gastroenterology. 2010. DOI: 10.3390/nu7064995
7. Day JW, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol. 2009. DOI: 10.1038/nchembio.209